Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 70, Issue 1, 2005, Pages 53-62

  Belcher, Glyn ^a   Lambert, Ceri ^a   Edwards, Gareth ^a   Urquhart, Richard ^a   Matthews, David R ^b  

^a Takeda Europe R and D Centre   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Gliclazide; Metformin; Pioglitazone; Safety and tolerability

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; GLICLAZIDE; LIVER ENZYME; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RHINOPHARYNGITIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLICLAZIDE; HEMATOCRIT; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOCYTE COUNT; MALE; METFORMIN; MIDDLE AGED; PLATELET COUNT; THIAZOLIDINEDIONES;

EID: 23944491714     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.02.011     Document Type: Article

References (28)

1. G.M. Reaven Banting lecture 1998. Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
2. G.M. Reaven Role of insulin resistance in human disease (syndrome X): an expanded definition Ann. Rev. Med. 44 1993 121 131
3. J.M. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists J. Clin. Invest. 106 2000 467 472
4. A. Benbow, M. Stewart, and G. Yeoman Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure BMJ 322 2001 236
5. Withdrawal of Troglitazone and Cisapride, JAMA 283 (2000) 2228.
6. M. Hanefeld, and G. Belcher Safety profile of pioglitazone Int. J. Clin. Pract. Suppl. 121 2001 27 31
7. G. Schernthaner, D. Matthews, B. Charbonnel, M. Hanefeld, and P. Brunetti Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial J. Clin. Endocrinol. Metab. 89 2004 6068 6076
8. B.H. Charbonnel, D.R. Matthews, G. Schernthaner, M. Hanefeld, P. Brunetti on behalf of the QUARTET Study Group, A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial, Diabet. Med. 22 (2005) 399-405.
9. M. Hanefeld, P. Brunetti, G.H. Schernthaner, D.R. Matthews, and B.H. Charbonnel One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes Diabetes Care 27 2004 141 147
10. D.R. Matthews, B.H. Charbonnel, M. Hanefeld, P. Brunetti, and G. Schernthaner Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study Diab. Metabol. Res. Rev. 21 2005 167 174
11. M.S. Kipnes, A. Krosnick, M.S. Rendell, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study Am. J. Med. 111 2001 10 17
12. D. Einhorn, M. Rendell, J. Rosenzweig, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group Clin. Ther. 22 2000 1395 1409
13. A.J. Krentz, R.E. Ferner, and C.J. Bailey Comparative tolerability profiles of oral antidiabetic agents Drug Saf. 11 1994 223 241
14. K.J. Palmer, R.N. Brogden, and Gliclazide An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus Drugs 46 1993 92 125
15. N.V. Niemeyer, and L.M. Janney Thiazolidinedione-induced edema Pharmacotherapy 22 2002 924 929
16. R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, and E.S. Horton Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 2004 256 263
17. HE. Lebovitz Differentiating members of the thiazolidinedione class: a focus on safety Diab. Metab. Res. Rev. 18 2002 S23 S29
18. NK. Hollenberg Considerations for management of fluid dynamic issues associated with thiazolidinediones Am. J. Med. 115 Suppl. 8A 2003 111S 115S
19. P. Dandona, A. Aljada, and A. Chaudhuri Vascular reactivity and thiazolidinediones Am. J. Med. 115 Suppl. 8A 2003 81 86
20. K. Filioussi, S. Bonovas, and T. Katsaros Should we screen diabetic patients using biguanides for megaloblastic anaemia? Aust. Fam. Phys. 32 2003 383 384
21. PVG. Katakam, MR. Ujhelyi, M. Hoenig, and AW. Miller Metformin improves vascular function in insulin-resistant rats Hypertension 35 2000 108 112
22. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
23. G. Pagano, G. Pacini, G. Musso, R. Gambino, F. Mecca, and N. Depetris Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association Hepatology 35 2002 367 372
24. BA. Neuschwander-Tetri, EM. Brunt, KR. Wehmeier, CA. Sponseller, K. Hampton, and BR. Bacon Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis J. Hepatol. 38 2003 434 440
25. S.H. Caldwell, E.E. Hespenheide, J.A. Redick, J.C. Iezzoni, E.H. Battle, and B.L. Sheppard A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis Am. J. Gastroenterol. 96 2001 519 525
26. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, and K. Cusi Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 2002 2784 2791
27. A.D. Harrower Comparison of efficacy, secondary failure rate, and complications of sulfonylureas J. Diab. Complicat. 8 1994 201 203
28. B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 2004 1647 1653